Jury calls for $162.5m damages in Teva propofol HCV exposure suit
This article was originally published in Scrip
Executive Summary
A Nevada jury ordered Teva Pharmaceutical Industries, Baxter Healthcare and McKesson to pay $162.5 million in total punitive damages to patients claiming to have acquired hepatitis C virus (HCV) from vials of the anaesthesia drug propofol, which had become contaminated after being reused in colonoscopy procedures in 2008.